In an effort to provide you with timely market feedback from ASCO 2013, OBR and MDoutlook are pleased to share results from MDoutlook’s fourth OncoPoll™ from the meeting exploring immunotherapy.
PD-1/PD-1L Antibody Treatments: Majority of Patients are Expected to Benefit from New Treatments
Clinical Importance of PD-1L Expression: US and Ex-US Oncologists Have Differing Views on the Importance of PD-1L Expression
Submitted by Jan Heybroek, President and Robert Stephan, Sr. Director Medical Services and Luan Dao, Global Medical Analyst, MDoutlook
You must be logged in to post a comment